Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors

Aromatase inhibitor (AI) is widely used as an endocrine treatment in postmenopausal patients with hormone receptor-positive breast cancer. To identify useful prognostic factors for patients with metastatic breast cancer treated with AI therapy, we investigated the association between several hormone receptor-related factors and prognosis. The expressions of estrogen receptor-α (ERα), ERβ, progesterone receptor, the phosphorylation of ERα serine 118 (Ser118) and ERα Ser167 were examined using immunohistochemical techniques for the primary tumors of 41 patients with metastatic breast cancer who received first-line AI therapy after relapse. To assess the associations of protein expression and phosphorylation levels with progression-free survival (PFS), the levels of each factor were categorized into low and high values at optimal cutoff points. In univariate analysis, high ERα expression and high ERα Ser167 phosphorylation correlated with longer PFS (p = 0.016 and 0.013, respectively). In multivariate analysis, low ERβ expression and high ERα Ser167 phosphorylation correlated with longer PFS (p = 0.031 and 0.004, respectively). Patients with both low ERβ expression and high ERα Ser167 phosphorylation had longer PFS than the others (p = 0.0107). These data suggest that the expression of ERβ and phosphorylation of ERα Ser167 may be useful prognostic factors in patients with metastatic breast cancer who received first-line AI therapy.

[1]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .

[2]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[3]  J. Gustafsson,et al.  Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.

[4]  J. Gustafsson.  An update on estrogen receptors. , 2000, Seminars in perinatology.

[5]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[6]  L. Murphy,et al.  Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo , 2004, Clinical Cancer Research.

[7]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[8]  J. Gustafsson,et al.  Estrogen Receptor β (ERβ) Level but Not Its ERβcx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer , 2004, Clinical Cancer Research.

[9]  S. Inoue,et al.  Clinical value of the wild-type estrogen receptor β expression in breast cancer , 2001 .

[10]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[11]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[12]  D. Lannigan.  Estrogen receptor phosphorylation , 2003, Steroids.

[13]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[14]  H. Yamashita,et al.  Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer , 2005, Breast Cancer Research.

[15]  T. Toyama,et al.  Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. , 2007, Japanese journal of clinical oncology.

[16]  H. Iwata,et al.  Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.

[17]  Arnold D K Hill,et al.  Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[19]  D. Siegmund,et al.  Maximally Selected Chi Square Statistics , 1982 .

[20]  A. Shaaban,et al.  Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers , 2004, British Journal of Cancer.

[21]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[22]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Vakaet.  Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2006, Journal of the National Cancer Institute.

[24]  L. Murphy,et al.  Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Kiesel,et al.  Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. , 2009, Anticancer research.

[26]  Y. Niu,et al.  Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer , 2002, British Journal of Cancer.

[27]  Satoru Takahashi,et al.  Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer , 2009, Cancer science.

[28]  Jerry Halpern,et al.  Maximally Selected Chi Square Statistics for Small Samples , 1982 .

[29]  J. Corton,et al.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. , 1998, Endocrinology.

[30]  H. Iwata,et al.  Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. , 2003, Cancer chemotherapy and pharmacology.

[31]  N. Kondo,et al.  Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. , 2008, Endocrine-related cancer.

[32]  A. Lazaris,et al.  The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer , 2004, Journal of Clinical Pathology.

[33]  J. Gustafsson,et al.  Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. Toyama,et al.  Expression of Estrogen Receptor β Wild-type and its Variant ERβcx/β2 is Correlated with Better Prognosis in Breast Cancer , 2007 .

[35]  R. Laucirica,et al.  Estrogen receptor beta expression in invasive breast cancer. , 2001, Human pathology.

[36]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[37]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[38]  S. Inoue,et al.  Clinical value of the wild-type estrogen receptor beta expression in breast cancer. , 2001, Cancer letters.

[39]  J. Blenis,et al.  pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167 , 1998, Molecular and Cellular Biology.

[40]  B. Katzenellenbogen,et al.  Estrogen receptors: selective ligands, partners, and distinctive pharmacology. , 2000, Recent progress in hormone research.

[41]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[42]  E. McDermott,et al.  Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer , 2004, British Journal of Cancer.